{"id":"voriconazole-preemptive-genotyping-strategy","safety":{"commonSideEffects":[{"rate":"20-30","effect":"Visual disturbances (photopsia, blurred vision)"},{"rate":"10-20","effect":"Hepatotoxicity (elevated transaminases)"},{"rate":"5-10","effect":"Rash"},{"rate":"5-10","effect":"Photosensitivity"},{"rate":"5-15","effect":"Hallucinations or neuropsychiatric effects"}]},"_chembl":{"chemblId":"CHEMBL638","moleculeType":"Small molecule","molecularWeight":"349.32"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Voriconazole is a triazole antifungal agent whose metabolism is highly dependent on CYP2C19 enzyme activity, which varies significantly among individuals due to genetic polymorphisms. By preemptively genotyping patients for CYP2C19 variants (poor metabolizers, intermediate metabolizers, extensive metabolizers, and ultra-rapid metabolizers), clinicians can adjust voriconazole dosing to maintain therapeutic drug levels while minimizing toxicity. This personalized medicine approach reduces the risk of subtherapeutic exposure or drug accumulation-related adverse effects.","oneSentence":"A pharmacogenomic strategy that uses CYP2C19 genotyping to optimize voriconazole dosing and reduce adverse events in individual patients.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-27T23:39:34.708Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Invasive aspergillosis"},{"name":"Candidemia and other Candida infections"},{"name":"Esophageal candidiasis"},{"name":"Scedosporium and Fusarium infections"}]},"trialDetails":[{"nctId":"NCT04238884","phase":"PHASE4","title":"Effectiveness and Efficiency of a Voriconazole Preemptive Genotyping Strategy","status":"UNKNOWN","sponsor":"Instituto de Investigación Hospital Universitario La Paz","startDate":"2020-01-02","conditions":"Invasive Fungal Infections","enrollment":146}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":1,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Voriconazole preemptive genotyping strategy","genericName":"Voriconazole preemptive genotyping strategy","companyName":"Instituto de Investigación Hospital Universitario La Paz","companyId":"instituto-de-investigaci-n-hospital-universitario-la-paz","modality":"Small molecule","firstApprovalDate":"","aiSummary":"A pharmacogenomic strategy that uses CYP2C19 genotyping to optimize voriconazole dosing and reduce adverse events in individual patients. Used for Invasive aspergillosis, Candidemia and other Candida infections, Esophageal candidiasis.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}